Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Biochem J ; 389(Pt 2): 527-39, 2005 Jul 15.
Article in English | MEDLINE | ID: mdl-15799720

ABSTRACT

Doxorubicin (DOX), a widely used antitumour drug, causes dose-dependent cardiotoxicity. Cardiac mitochondria represent a critical target organelle of toxicity during DOX chemotherapy. Proposed mechanisms include generation of ROS (reactive oxygen species) and disturbances in mitochondrial calcium homoeostasis. In the present study, we probed the mechanistic link between mitochondrial ROS and calcium in the embryonic rat heart-derived H9c2 cell line and in adult rat cardiomyocytes. The results show that DOX stimulates calcium/calcineurin-dependent activation of the transcription factor NFAT (nuclear factor of activated T-lymphocytes). Pre-treatment of cells with an intracellular calcium chelator abrogated DOX-induced nuclear NFAT translocation, Fas L (Fas ligand) expression and caspase activation, as did pre-treatment of cells with a mitochondria-targeted antioxidant, Mito-Q (a mitochondria-targeted antioxidant consisting of a mixture of mitoquinol and mitoquinone), or with adenoviral-over-expressed antioxidant enzymes. Treatment with GPx-1 (glutathione peroxidase 1), MnSOD (manganese superoxide dismutase) or a peptide inhibitor of NFAT also inhibited DOX-induced nuclear NFAT translocation. Pre-treatment of cells with a Fas L neutralizing antibody abrogated DOX-induced caspase-8- and -3-like activities during the initial stages of apoptosis. We conclude that mitochondria-derived ROS and calcium play a key role in stimulating DOX-induced 'intrinsic and extrinsic forms' of apoptosis in cardiac cells with Fas L expression via the NFAT signalling mechanism. Implications of ROS- and calcium-dependent NFAT signalling in DOX-induced apoptosis are discussed.


Subject(s)
Calcium/metabolism , Doxorubicin/pharmacology , Membrane Glycoproteins/genetics , Mitochondria, Heart/drug effects , NFATC Transcription Factors/metabolism , Nerve Tissue Proteins/metabolism , Reactive Oxygen Species/metabolism , Transcription, Genetic/drug effects , Tumor Necrosis Factors/genetics , Animals , Apoptosis/drug effects , Calcium/antagonists & inhibitors , Caspases/metabolism , Cell Line , Cell Nucleus/drug effects , Cell Nucleus/metabolism , Enzyme Activation/drug effects , Fas Ligand Protein , Gene Expression Regulation/drug effects , Hydrogen Peroxide/pharmacology , Male , Mitochondria, Heart/metabolism , Myocytes, Cardiac/cytology , Myocytes, Cardiac/metabolism , NFATC Transcription Factors/antagonists & inhibitors , Nerve Tissue Proteins/antagonists & inhibitors , Oxidative Stress , Rats , Rats, Sprague-Dawley , Signal Transduction/drug effects , Up-Regulation
2.
J Lipid Res ; 46(2): 342-9, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15576840

ABSTRACT

N-arachidonylethanolamine (AEA) accumulates during brain injury and postmortem. Because fatty acid amide hydrolase (FAAH) regulates brain AEA content, the purpose of this study was to determine its role in the postmortal accumulation of AEA using FAAH null mice. As expected, AEA content in immediately frozen brain tissue was significantly greater in FAAH-deficient (FAAH-/-) than in wild-type mice. However, AEA content was significantly lower in brains from FAAH-/- mice at 5 and 24 h postmortem. Similarly, wild-type mice treated in vivo with a FAAH inhibitor (URB532) had significantly lower brain AEA content 24 h postmortem compared with controls. These data indicate that FAAH contributes significantly to the postmortal accumulation of AEA. In contrast, the accumulations of two other N-acylethanolamines, N-oleoylethanolamine (OEA) and N-palmitoylethanolamine (PEA), were not reduced at 24 h postmortem in either the FAAH-/- mice or mice treated with URB532. FAAH-/- mice accumulated significantly less ethanolamine at 24 h postmortem compared with wild-type mice, suggesting that FAAH activity plays a role in the accumulation of ethanolamine postmortem. These data demonstrate that FAAH activity differentially affects AEA and OEA/PEA contents postmortem and suggest that AEA formation specifically occurs via an ethanolamine-dependent route postmortem.


Subject(s)
Amidohydrolases/metabolism , Arachidonic Acids/biosynthesis , Brain/metabolism , Amides , Animals , Endocannabinoids , Ethanolamine/metabolism , Ethanolamines/metabolism , Female , Hydrolysis , Lipid Metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Inbred ICR , Mice, Transgenic , Oleic Acids , Palmitic Acids/metabolism , Pisum sativum/metabolism , Phosphatidylethanolamines/metabolism , Polyunsaturated Alkamides , Postmortem Changes , Time Factors
3.
J Biol Chem ; 279(15): 15240-7, 2004 Apr 09.
Article in English | MEDLINE | ID: mdl-14742448

ABSTRACT

1-Methyl-4-phenylpyridinium (MPP(+)) is a neurotoxin that causes Parkinson's disease in experimental animals and humans. Despite the fact that intracellular iron was shown to be crucial for MPP(+)-induced apoptotic cell death, the molecular mechanisms for the iron requirement remain unclear. We investigated the role of transferrin receptor (TfR) and iron in modulating the expression of alpha-synuclein (alpha-syn) in MPP(+)-induced oxidative stress and apoptosis. Results show that MPP(+) inhibits mitochondrial complex-1 and aconitase activities leading to enhanced H(2)O(2) generation, TfR expression and alpha-syn expression/aggregation. Pretreatment with cell-permeable iron chelators, TfR antibody (that inhibits TfR-mediated iron uptake), or transfection with glutathione peroxidase (GPx1) enzyme inhibits intracellular oxidant generation, alpha-syn expression/aggregation, and apoptotic signaling as measured by caspase-3 activation. Cells overexpressing alpha-syn exacerbated MPP(+) toxicity, whereas antisense alpha-syn treatment totally abrogated MPP(+)-induced apoptosis in neuroblastoma cells without affecting oxidant generation. The increased cytotoxic effects of alpha-syn in MPP(+)-treated cells were attributed to inhibition of mitogen-activated protein kinase and proteasomal function. We conclude that MPP(+)-induced iron signaling is responsible for intracellular oxidant generation, alpha-syn expression, proteasomal dysfunction, and apoptosis. Relevance to Parkinson's disease is discussed.


Subject(s)
Apoptosis , Hydrogen Peroxide/pharmacology , Iron/metabolism , Nerve Tissue Proteins/metabolism , Neuroblastoma/metabolism , Receptors, Transferrin/metabolism , Up-Regulation , 1-Methyl-4-phenylpyridinium/pharmacology , Antioxidants/pharmacology , Blotting, Western , Caspase 3 , Caspases/metabolism , Cell Line, Tumor , Chelating Agents/pharmacology , Cysteine Endopeptidases/metabolism , Glutathione Peroxidase/metabolism , Herbicides/pharmacology , Humans , Iron/pharmacology , MAP Kinase Signaling System , Models, Biological , Multienzyme Complexes/metabolism , Oligonucleotides, Antisense/pharmacology , Oxidants/metabolism , Oxidative Stress , Proteasome Endopeptidase Complex , Receptors, Transferrin/biosynthesis , Receptors, Transferrin/physiology , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Synucleins , Time Factors , Transfection , alpha-Synuclein
4.
Biochem J ; 371(Pt 1): 151-64, 2003 Apr 01.
Article in English | MEDLINE | ID: mdl-12523938

ABSTRACT

1-Methyl-4-phenylpyridinium (MPP(+)) is a neurotoxin used in cellular models of Parkinson's Disease. Although intracellular iron plays a crucial role in MPP(+)-induced apoptosis, the molecular signalling mechanisms linking iron, reactive oxygen species (ROS) and apoptosis are still unknown. We investigated these aspects using cerebellar granule neurons (CGNs) and human SH-SY5Y neuroblastoma cells. MPP(+) enhanced caspase 3 activity after 24 h with significant increases as early as 12 h after treatment of cells. Pre-treatment of CGNs and neuroblastoma cells with the metalloporphyrin antioxidant enzyme mimic, Fe(III)tetrakis(4-benzoic acid)porphyrin (FeTBAP), completely prevented the MPP(+)-induced caspase 3 activity as did overexpression of glutathione peroxidase (GPx1) and pre-treatment with a lipophilic, cell-permeable iron chelator [N, N '-bis-(2-hydroxybenzyl)ethylenediamine-N, N '-diacetic acid, HBED]. MPP(+) treatment increased the number of TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick-end-labelling)-positive cells which was completely blocked by pre-treatment with FeTBAP. MPP(+) treatment significantly decreased the aconitase and mitochondrial complex I activities; pre-treatment with FeTBAP, HBED and GPx1 overexpression reversed this effect. MPP(+) treatment increased the intracellular oxidative stress by 2-3-fold, as determined by oxidation of dichlorodihydrofluorescein and dihydroethidium (hydroethidine). These effects were reversed by pre-treatment of cells with FeTBAP and HBED and by GPx1 overexpression. MPP(+)-treatment enhanced the cell-surface transferrin receptor (TfR) expression, suggesting a role for TfR-induced iron uptake in MPP(+) toxicity. Treatment of cells with anti-TfR antibody (IgA class) inhibited MPP(+)-induced caspase activation. Inhibition of nitric oxide synthase activity did not affect caspase 3 activity, apoptotic cell death or ROS generation by MPP(+). Overall, these results suggest that MPP(+)-induced cell death in CGNs and neuroblastoma cells proceeds via apoptosis and involves mitochondrial release of ROS and TfR-dependent iron.


Subject(s)
1-Methyl-4-phenylpyridinium/pharmacology , Apoptosis/drug effects , Edetic Acid/analogs & derivatives , Hydrogen Peroxide/metabolism , Iron/metabolism , Mitochondria/metabolism , Receptors, Transferrin/metabolism , Aconitate Hydratase/drug effects , Aconitate Hydratase/metabolism , Animals , Antioxidants/pharmacology , Caspase 3 , Caspases/drug effects , Caspases/metabolism , Cells, Cultured , Deferoxamine/pharmacology , Edetic Acid/pharmacology , Female , Glutathione Peroxidase/drug effects , Glutathione Peroxidase/genetics , Glutathione Peroxidase/metabolism , Humans , Iron Chelating Agents/pharmacology , Male , Metalloporphyrins/pharmacology , Mitochondria/drug effects , NADH, NADPH Oxidoreductases/metabolism , Neurons/drug effects , Neurons/metabolism , Oxidants/metabolism , Oxidative Stress , Parkinson Disease/metabolism , Parkinson Disease/pathology , Reactive Oxygen Species/metabolism , Receptors, Transferrin/drug effects , Receptors, Transferrin/immunology , Staining and Labeling/methods , Transferrin/metabolism , Glutathione Peroxidase GPX1
SELECTION OF CITATIONS
SEARCH DETAIL
...